Renal cell carcinoma

被引:125
作者
Rini, Brian I. [2 ]
Rathmell, W. Kimryn [1 ]
Godley, Paul [1 ]
机构
[1] Univ N Carolina, Lineberger Canc Res Ctr, Div Hematol & Oncol, Chapel Hill, NC 27599 USA
[2] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA
关键词
antiangiogenesis; mammalian target of rapamycin; multitargeted kinase inhibitor; renal cell carcinoma; von Hippel-Lindau;
D O I
10.1097/CCO.0b013e3282f9782b
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review The recent contributions to renal cell carcinoma in the fields of molecular biology and the expanded use of molecularly targeted agents will be reviewed. This study is intended to update prognostic and therapeutic decision-making data and provide perspective on advances in understanding the molecular biology of this disease. Recent findings Updates to the currently used prognostic algorithms for renal cell carcinoma are needed, and recently verified prognostic nomograms will be discussed. This comes in the wake of numerous advances in the use of molecularly targeted drugs, which will be reviewed. Finally, advancements in understanding the biology of renal cell carcinoma include the discovery of von Hippel-Linclau associated mechanisms involved in renal cyst formation and renewed appreciation for the influence of this pathway on the tumor cell glucose utilization profile. Summary Renal cell carcinoma continues to evolve swiftly with the approval of new agents and the maturation of clinical trials to provide relevant structure to treatment decisions. This study will give an overview of the latest concepts in the epidemiology and biology of renal cell carcinoma and provide current surgical and systemic updates for managing renal cell carcinoma.
引用
收藏
页码:300 / 306
页数:7
相关论文
共 48 条
[1]  
*AM CANC SOC, 2007, CANC FACTS FIG 2007
[2]  
Amato RJ, 2007, J CLIN ONCOL, V25
[3]   Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].
Atkins, MB ;
Hidalgo, M ;
Stadler, WM ;
Logan, TF ;
Dutcher, JP ;
Hudes, GR ;
Park, Y ;
Lion, SH ;
Marshall, B ;
Boni, JP ;
Dukart, G ;
Sherman, ML .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918
[4]   Pseudohypoxic pathways in renal cell carcinoma [J].
Bratslavsky, Gennady ;
Sudarshan, Sunil ;
Neckers, Len ;
Linehan, W. Marston .
CLINICAL CANCER RESEARCH, 2007, 13 (16) :4667-4671
[5]  
BUKOWSKI RM, 2007, J CLIN ONCOL, V25
[6]  
Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154
[7]   Randomized trial of laparoscopic v open nephrectomy [J].
Burgess, Neil A. ;
Koo, Brendan C. ;
Calvert, Robert C. ;
Hindmarsh, Andrew ;
Donaldson, Peter J. ;
Rhodes, Michael .
JOURNAL OF ENDOUROLOGY, 2007, 21 (06) :610-613
[8]  
Escudier B, 2007, J CLIN ONCOL, V25
[9]   Phase I trial of sorafenib in combination with IFN α-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma [J].
Escudier, Bernard ;
Lassau, Nathalie ;
Angevin, Eric ;
Soria, Jean Charles ;
Chami, Linda ;
Lamuraglia, Michele ;
Zafarana, Eric ;
Landreau, Veronique ;
Schwartz, Brian ;
Brendel, Eric ;
Armand, Jean-Pierre ;
Robert, Caroline .
CLINICAL CANCER RESEARCH, 2007, 13 (06) :1801-1809
[10]   Sorafenib in advanced clear-cell renal-cell carcinoma [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Siebels, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Solska, Ewa ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Freeman, Scott ;
Schwartz, Brian ;
Shan, Minghua ;
Simantov, Ronit ;
Bukowski, Ronald M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134